Wegovy weight loss pill now available in UK – here’s what you need to know
Monday, July 6 – The once-a-day pill, from the makers of the Wegovy weight-loss jab, can now be bought privately in UK pharmacies.
Twice-Monthly GLP-1 Shot Helps Manage Blood Sugar, Weight Loss in Trial
Saturday, July 4 – A new biweekly GLP-1 injection has been shown to significantly reduce blood sugar in a clinical trial. Image Credit: Hannes P Albert/picture alliance via Getty Images
A new GLP-1 medication demonstrated efficacy in reducing blood sugar in people with type 2 diabetes in a phase 2b clinical trial.
Bofanglutide is a biweekly (once every 2 weeks) injection compared to once-weekly shots like Ozempic and Wegovy.
Medicare Is Now Covering Some GLP-1s for Weight-Loss for $50. Here’s What to Know
Saturday, July 4 – (MedPage Today) — Popular — and expensive — GLP-1 agonists for weight loss just got a lot cheaper for many older Americans.
Starting this week, the federal government is offering a selection of the brand name medications to certain Medicare…
Semaglutide may lower risk of serious complications in high-risk diabetes
Friday, July 3 – Semaglutide may lower risk of serious complications in high-risk diabetes
FDA takes aim at misleading online claims for compounded GLP-1 drugs
Saturday, July 4 – On June 16, 2026, the US Food and Drug Administration (FDA) issued 25 warning letters to various telehealth companies alleging that their websites contained false or misleading claims about compounded semaglutide, tirzepatide, and, in one case, liraglutide products….By: McDermott Will & Schulte
7 things to know about Medicare’s new GLP-1 coverage
Friday, July 3 – For decades, it’s been against the law for Medicare to pay for weight-loss medication. But that changed on July 1, with the launch of a new program called Bridge. It gives some people over 65, or who have Medicare for other reasons, access to some weight management medications if they meet certain weight and health criteria.
GLP-1 Receptor Agonist Exposures Reported to Poison Center Up After FDA Approval for Weight Loss
WEDNESDAY, July 1, 2026 — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) exposures reported to U.S. poison centers increased following 2021 U.S. Food and Drug Administration (FDA) approval for weight loss, according to a study published in the…
GLP-1 Receptor Agonist Exposures Reported to Poison Center Up After FDA Approval for Weight Loss
WEDNESDAY, July 1, 2026 — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) exposures reported to U.S. poison centers increased following 2021 U.S. Food and Drug Administration (FDA) approval for weight loss, according to a study published in…
GLP-1 drugs outperform SGLT-2 drugs for patients with Afib and type 2 diabetes
Thursday, July 2 – Individuals with atrial fibrillation (Afib), or irregular heart rhythm, are at increased risk of stroke, chronic kidney disease and heart failure. These risks are significantly exacerbated if a type 2 diabetes diagnosis is added to the mix, says Md Mohaimenul Islam, Ph.D., research assistant professor in the Department of Pharmacy Practice in the University at Buffalo School of Pharmacy and Pharmaceutical Sciences.
GLP-1s Linked to Systemic Clinical Risk Reduction in Hidradenitis Suppurativa
Thursday, July 2 – (MedPage Today) — Patients with hidradenitis suppurative (HS) and a history of GLP-1 receptor agonist use for diabetes or obesity had significantly lower rates of multiple cardiovascular events and mortality, a large retrospective cohort study…